SINGULAIR

SINGULAIR- montelukast sodium granule
SINGULAIR- montelukast sodium tablet, chewable
SINGULAIR- montelukast sodium tablet, film coated
Organon LLC

WARNING: SERIOUS NEUROPSYCHIATRIC EVENTS

Serious neuropsychiatric (NP) events have been reported with the use of SINGULAIR. The types of events reported were highly variable, and included, but were not limited to, agitation, aggression, depression, sleep disturbances, suicidal thoughts and behavior (including suicide). The mechanisms underlying NP events associated with SINGULAIR use are currently not well understood [see Warnings and Precautions (5.1)].
Because of the risk of NP events, the benefits of SINGULAIR may not outweigh the risks in some patients, particularly when the symptoms of disease may be mild and adequately treated with alternative therapies. Reserve use of SINGULAIR for patients with allergic rhinitis who have an inadequate response or intolerance to alternative therapies [see Indications and Usage (1.3)]. In patients with asthma or exercise-induced bronchoconstriction, consider the benefits and risks before prescribing SINGULAIR. Discuss the benefits and risks of SINGULAIR with patients and caregivers when prescribing SINGULAIR. Advise patients and/or caregivers to be alert for changes in behavior or new NP symptoms when taking SINGULAIR. If changes in behavior are observed, or if new NP symptoms or suicidal thoughts and/or behavior occur, advise patients to discontinue SINGULAIR and contact a healthcare provider immediately [see Warnings and Precautions (5.1)].

1 INDICATIONS AND USAGE

1.1 Asthma

SINGULAIR® is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older.

1.2 Exercise-Induced Bronchoconstriction (EIB)

SINGULAIR is indicated for prevention of exercise-induced bronchoconstriction (EIB) in patients 6 years of age and older.

1.3 Allergic Rhinitis

SINGULAIR is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older. Because the benefits of SINGULAIR may not outweigh the risk of neuropsychiatric symptoms in patients with allergic rhinitis [see Warnings and Precautions (5.1)] , reserve use for patients who have an inadequate response or intolerance to alternative therapies.

1.4 Limitations of Use

SINGULAIR is not indicated for the treatment of an acute asthma attack.

2 DOSAGE AND ADMINISTRATION

2.1 Asthma

For asthma, administer SINGULAIR orally once daily in the evening, with or without food. There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing.

The following doses are recommended:

Table 1: Recommended Dosage in Asthma
Age Dose
*
Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.
Adult and adolescent patients 15 years of age and older one 10 mg tablet
Pediatric patients 6 to 14 years of age one 5 mg chewable tablet
Pediatric patients 2 to 5 years of age one 4 mg chewable tablet or one packet of oral granules
Pediatric patients 12 to 23 months of age * one packet 4 mg oral granules

Patients who miss a dose should take the next dose at their regular time and should not take 2 doses at the same time.

2.2 Exercise-Induced Bronchoconstriction (EIB)

For prevention of EIB, administer a single dose of SINGULAIR orally at least 2 hours, before exercise. The following doses are recommended:

Table 2: Recommended Dosage in Exercise-Induced Bronchoconstriction (EIB)
Age Dose
*
Safety and effectiveness in patients younger than 6 years of age have not been established.
Adult and adolescent patients 15 years of age and older one 10 mg tablet
Pediatric patients 6 to 14 years of age * one 5 mg chewable tablet

An additional dose of SINGULAIR should not be taken within 24 hours of a previous dose. Patients already taking SINGULAIR daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist.

Daily administration of SINGULAIR for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.

2.3 Allergic Rhinitis

For allergic rhinitis, administer SINGULAIR orally once daily without regard to time of food ingestion. Time of administration in patients with allergic rhinitis can be individualized to suit patient needs.

The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended:

Table 3: Recommended Dosage in Seasonal Allergic Rhinitis
Age Dose
*
Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.
Adult and adolescent patients 15 years of age and older one 10 mg tablet
Pediatric patients 6 to 14 years of age one 5 mg chewable tablet
Pediatric patients 2 to 5 years of age * one 4 mg chewable tablet or one packet of 4 mg oral granules

The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended:

Table 4: Recommended Dosage in Perennial Allergic Rhinitis
Age Dose
*
Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established.
Adult and adolescent patients 15 years of age and older one 10 mg tablet
Pediatric patients 6 to 14 years of age one 5 mg chewable tablet
Pediatric patients 2 to 5 years of age one 4 mg chewable tablet or one packet of 4 mg oral granules
Pediatric patients 6 to 23 months of age * one packet of 4 mg oral granules

Patients who miss a dose should take the next dose at their regular time and should not take 2 doses at the same time.

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2021. All Rights Reserved.